|
See related CoPlavix film-coated tab information |
|
|
|
Manufacturer |
sanofi-aventis |
|
Distributor |
DKSH |
|
Contents |
Clopidogrel hydrogen sulphate 75 mg, acetylsalicylic acid 75 mg |
|
Indications |
Prevention of atherothrombotic events. Continuation of therapy in non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI) including patients undergoing stent placement following percutaneous coronary intervention; ST-segment elevation acute MI in patients eligible for thrombolytic therapy.
Click to view CoPlavix detailed prescribing infomation |
|
Dosage |
Adult & elderly 1 tab as single daily dose.
Click to view CoPlavix detailed prescribing infomation |
|
Overdosage |
View CoPlavix overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Hypersensitivity to NSAIDs. Syndrome of asthma, rhinitis & nasal polyps; severe hepatic & renal impairment; active pathological bleeding eg peptic ulcer or intracranial haemorrhage. Pregnancy (3rd trimester).
Click to view CoPlavix detailed prescribing infomation |
|
Special Precautions |
Patients at risk of increased bleeding; lesions w/ propensity to bleed particularly GI & intraocular. Thrombotic thrombocytopenic purpura; recent transient ischaemic attack or stoke; CYP2C19 poor metabolisers; gout; history of asthma, allergic disorders, peptic ulcer, gastroduodenal haemorrhage or minor upper GI symptoms; moderate hepatic impairment; galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption as it contains lactose. Discontinue 7 days prior to surgery. Childn & adolescents <18 yr. Pregnancy (1st & 2nd trimester). Lactation.
Click to view CoPlavix detailed prescribing infomation |
|
Adverse Drug Reactions |
Bleeding, haematoma, epistaxis, GI haemorrhage, diarrhoea, abdominal pain, dyspepsia, bruising.
View ADR Monitoring Form |
|
Drug Interactions |
Anticoagulants, gylcoprotein IIb/IIIA inhibitors, heparin, thrombolytics, NSAIDs including COX-2 inhibitors, CYP2C19 inhibitors, uricosurics, methotrexate.
View more drug interactions with CoPlavix |
|
Storage |
View CoPlavix storage conditions for details to ensure optimal shelf-life. |
|
Description |
View CoPlavix description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View CoPlavix mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
CoPlavix film-coated tablet |
|
|
|
Manufacturer: |
sanofi-aventis |
|
Distributor: |
DKSH
|
|
|
|
